BBNX — Beta Bionics, Inc.

Summary of Beta Bionics Q2 2026 Earnings Call

1. Key Financial Results and Metrics:

• Net Sales: $32 million, a 38% increase year-over-year.
• Gross Margin: 59%, up 524 basis points year-over-year, though down 45 basis points from the previous quarter.
• Operating Expenses: $44.5 million, a 37% increase year-over-year, driven by sales and marketing expansion and R&D investments.
• Cash Position: Approximately $225 million in cash and investments, indicating strong capitalization for ongoing initiatives.

2. Strategic Updates and Business Highlights:

• Patient Growth: New patient starts increased by over 10% but less than 20% compared to the prior quarter, with approximately 69% coming from users previously on multiple daily injections.
• Pharmacy Channel: High retention rates in the pharmacy channel, with 30% of new patient starts reimbursed through this channel.
• Real-World Data Transparency: Launched a live data dashboard for iLet users, enhancing data accessibility and transparency.
• Innovation Pipeline:
  • Mint Patch Pump: Expected full commercial launch by Q2 2027, with significant progress in manufacturing readiness.
  • Bihormonal System: Ongoing Phase 2a trials with improvements identified for the system.
  • Type 2 Diabetes Indication: Initiated a pivotal trial to expand iLet's indications to include adults with Type 2 diabetes, with enrollment starting in July.

3. Forward Guidance and Outlook:

• Revenue Guidance: Reiterated full-year revenue guidance of $131 million to $136 million.
• Gross Margin Outlook: Raised to 58.5% to 59.5% for the full year, reflecting strong performance and expectations for continued contributions from the pharmacy installed base.
• Operating Expenses: Anticipated modest increase in the second half, primarily due to sales and R&D expenses.

4. Bad News, Challenges, or Points of Concern:

• Warranty Costs: While gross margin improved, the warranty expense decrease was attributed to product improvements rather than retention metrics, raising questions about long-term user satisfaction.
• Stocking Dynamics: Pharmacy supply revenue was lower than expected due to inventory management by pharmacy customers, which could impact future revenue.
• Competitive Pressures: New entrants in the pharmacy channel may increase competition, although management believes their differentiated product offering will mitigate this risk.

5. Notable Q&A Insights:

• Data Accessibility: Management emphasized efforts to ensure healthcare providers are aware of the new live data portal for iLet users.
• Competitive Landscape: Management noted that while new competitors are entering the market, they believe their product's unique value proposition will maintain their market position.
• Sales Territories: The addition of 20 new sales territories is expected to enhance productivity in the second half of the year, with historical trends suggesting a more favorable Q4.
• Pharmacy Coverage for Mint: Management indicated that existing relationships with PBMs will facilitate faster coverage for Mint, although they do not expect to match competitors' coverage levels immediately upon launch.

Overall, Beta Bionics reported strong growth in Q2 2026, with a focus on expanding its market presence and enhancing product offerings, while navigating challenges related to competition and inventory management.